The glaucoma therapeutics market achieved a substantial milestone in 2021, reaching a valuation of US$ 6.6 billion. Over the next decade, it is poised to grow at an impressive rate, projected to be 1.5 times its current size, with a target of US$ 10 billion by 2031.
Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4775
The glaucoma therapeutics market presents a substantial growth opportunity due to several factors. Firstly, the aging population is a significant driver, as glaucoma becomes more prevalent with age. Additionally, increasing awareness about eye health, technological advancements in diagnosis and treatment, and expanding access to healthcare in emerging economies contribute to the market's growth. Moreover, the rising adoption of combination therapies and minimally invasive surgical procedures is opening new avenues for market expansion.
Despite the promising growth prospects, the glaucoma therapeutics market faces several challenges. One major obstacle is the underdiagnosis and undertreatment of glaucoma, especially in developing regions, where access to healthcare resources may be limited. Additionally, patient adherence to treatment regimens, which often involve daily eye drops, can be poor, impacting treatment efficacy. The high cost of some glaucoma medications and surgical procedures may also limit access to care for some patients.
- Allergan Plc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Santen Pharmaceuticals Co. Ltd.
- Valeant Pharmaceuticals Inc.
- Aerie Pharmaceuticals Inc.
Strategic collaborations between manufacturers have proven to be instrumental in boosting production capacity and meeting the ever-growing demands of consumers. This, in turn, leads to a significant increase in revenue and market share. Moreover, the introduction of innovative products and cutting-edge technologies not only caters to the needs of end-users but also ensures that these products are environmentally friendly.
In a noteworthy development, the U.S Food & Drug Administration granted approval to Allergan Plc.'s DURYSTATM (bimatoprost implant) New Drug Application in May 2020. This groundbreaking drug represents one of the first intracameral, sustained-release implants designed to effectively reduce intraocular pressure (IOP) in patients suffering from open-angle glaucoma or ocular hypertension.
Furthermore, in a commendable move, Novartis AG has made a commitment to collaborate with partners worldwide to combat preventable visual impairment and blindness. By reimagining access to eye care, the company aims to make a significant impact in eliminating these conditions. As part of this initiative, Novartis AG has joined forces with the International Agency for the Prevention of Blindness during the World Sight Day to launch the impactful #LoveYourEyes campaign.
Key Segments Covered
- Drug Class
- Beta Blockers
- Alpha Agonists
- Carbonic Anhydrase Inhibitors
- Combination Medications
- Cholinergic Medications
- End User
- Ophthalmic Clinics
- Ambulatory Surgical Centers
Get Customization on this Report for Specific Research Solutions: https://www.factmr.com/connectus/sample?flag=RC&rep_id=4775
About Fact.MR :
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
US Sales Office
11140 Rockville Pike
Suite 400 Rockville, MD 20852
United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: [email protected]